Medicenna Therapeutics Corp. MDNA.TO
Set alert
As of Oct 30, 3:54 PM ET
- YTD
- -50.54%
- 1 year
- -69.26%
- Open
- 0.48
- Prev close
- 0.48
- Mkt cap
- 42.00M
- Vol
- 95.90K
- Avg vol
- 48.01K
- EPS
- -0.22
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.445
- High
- 0.48
- Forward P/E
- -8.00
- Beta
- 1.19
- Short ratio
- 0.55
- Inst. own
- 12.77%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.96
- 200-d avg
- 2.03
- 1y target
- 4.38
2Y chart
Events in this range
- Dec 6, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (72)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 27, 2026 | 5 days ago |
| MACD: Sell Signal | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| SMA: Bullish | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| RSI: Overbought | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 21, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| RSI: Oversold | Jul 16, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| MACD: Sell Signal | May 15, 2026 | 5 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| RSI: Oversold | Mar 23, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| SMA: Bullish | Feb 26, 2026 | 8 months ago |
| SMA: Bearish | Feb 24, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 10, 2026 | 8 months ago |
| RSI: Oversold | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| RSI: Oversold | Dec 18, 2025 | 10 months ago |
| SMA: Bullish | Dec 16, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 11, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 4, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 12, 2025 | 11 months ago |
| RSI: Overbought | Oct 24, 2025 | 1 year ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 23, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 21, 2025 | 1 year ago |
| SMA: Bearish | Sep 24, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 22, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | May 28, 2025 | 1 year ago |
| MACD: Sell Signal | May 23, 2025 | 1 year ago |
| MACD: Buy Signal | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| RSI: Overbought | May 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 8, 2025 | 1 year ago |
| RSI: Oversold | Apr 4, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| RSI: Oversold | Feb 5, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 20, 2025 | 1 year ago |
| RSI: Oversold | Jan 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 3, 2025 | 1 year ago |
Key statistics
- Market cap
- 143.81M
- Enterprise value
- 75.73M
- Trailing P/E
- 0.00
- Forward P/E
- -8.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 24.53
- EPS (TTM)
- -0.38
- Beta
- 1.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.38K
- Total cash
- 35.63M
- Total debt
- 0
- Return on equity
- -105.43%
- Shares outstanding
- 78.16M
- Short % of float
- 0.15%
- 50-day average
- 1.96
- 200-day average
- 2.03
Analyst view
Consensus: none
- Target (low)
- 3.75
- Target (mean)
- 4.38
- Target (high)
- 5.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 18, 2020 | Oppenheimer | init | — | Outperform |
| Dec 17, 2020 | Oppenheimer | init | — | Outperform |
| Sep 10, 2020 | HC Wainwright & Co. | init | — | Buy |
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- medicenna.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MDNA.TO — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Org Partners LLC | 0.16% | 125,000 | 230.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 34,144 | 62.82K | Oct 30, 2023 |